Skip to content
Politically.com Search all
Menu

2025 · 1st Quarter (Jan 1 - Mar 31)

GENENTECH

Filed by CAPITOL COUNSEL LLC.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 21, 2025
Income
$50,000.00
Expenses
Not reported
Client
GENENTECH
Filing UUID
9a231fd5-67ac-4a19-867f-c49070f314b3
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements. Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.

HCR · Health Issues

340B Program issues and patient access to pharmaceuticals. Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy. Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains. Enhanced FDA reporting and risk mitigation plans for certain medicines. Incentives for antimicrobial and antiviral research, medical countermeasures, and novel product development.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.